Corvus Pharma’s HIV Candidate Shows Potential To Prevent Virus Re-Emergence
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) announced new data demonstrating the potential of CPI-818, an ITK inhibitor, to reduce the need for chronic…
$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades.
4 Penny Stocks Insiders Are Buying: Getaround, Corvus Pharmaceuticals And More
The Dow Jones closed lower by over 700 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Corvus Pharmaceuticals Presents Updated Data From CPI-818 Phase 1/1b Clinical Trial At The 64th American Society Of Hematology Annual Meeting & Exposition
Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Earnings Preview For Corvus Pharmaceuticals
Corvus Pharmaceuticals (NASDAQ:CRVS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement.
Analysts estimate that Corvus Pharmaceuticals will report an earnings per share (EPS) of $-0.16.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 361 companies set new 52-week lows.
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For Phase 1/1b Clinical Trial Of Mupadolimab In China
BURLINGAME, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application to initiate
Corvus Pharmaceuticals: Q2 Earnings Insights
Corvus Pharmaceuticals (NASDAQ:CRVS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.